Welcome to STAT’s Biotech Q1 Scorecard, our emoji-enabled means of tracking 11 make-or-break events expected over the next three months. When each clinical trial or FDA decision crosses the wires, we’ll add in the appropriate sunglassed smiley, rocket ship, or, if merited, smiling pile of excrement. Read on for brief explanations of what we’re watching for from each company.

(If you’re wondering why Axovant Sciences (AXON) and AveXis (AVXS) are missing, it’s because they got ahead of the rest of the pack. For Axovant’s compound misfortune of trial failure and embarrassing correction, let’s go with this emoji; for AveXis’ situation with the FDA, we’ll do this one.)

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy